The purpose of this Handbook is to provide a practical source of information on laws related to TB control to help public health practitioners and their legal counsel to: (1) understand the legal environment for the control of communicable diseases, including TB; (2) identify and explain legal issues in TB control; and (3) consider the use of tools for improving TB control.
The purpose of the Menu is to provide a set of optional provisions for consideration by public health officials and their legal counsel in their efforts to eliminate tuberculosis.
The white paper, or policy document, outlines the strategic vision of NCHHSTP for reducing health disparities and promoting health equity among populations affected by these diseases. NCHHSTP is committed to promoting awareness, stakeholder and community engagement, and action on factors that can affect the nation and the world's health; to addressing these factors in the policy, practice, and research activities of NCHHSTP; and to building partnerships on every level.
This document is intended to raise awareness about TB/HIV research priorities (i.e. areas that require urgent funding and scientific interest), help coordinate advocacy efforts, and encourage research funding. The aim is to increase the implementation of high-quality, integrated TB/HIV interventions in resource-limited settings. The document outlines a revised research priority agenda based on the latest evidence in six key areas of TB and HIV co-infection.
This report highlights the issues surrounding high prices and poor supply of the drugs needed to treat drug-resistant tuberculosis (DR-TB). The report provides an overview of available drug-resistant TB medicines, including drug sources, quality status, and price.
The Global Drug Facility (GDF) is a mechanism to expand access to, and availability of, high-quality anti-TB drugs and diagnostics to support the Stop TB Strategy.
This document outlines progress that GDF has made to date, what still needs to be done and where high-level advocacy could help GDF to further scale up its activities.
The Global Drug Facility (GDF) is a mechanism to expand access to, and availability of, high-quality anti-TB drugs and diagnostics to support the Stop TB Strategy.
This document outlines progress that GDF has made to date, what still needs to be done and where high-level advocacy could help GDF to further scale up its activities.
The guidelines show how people with HIV can be protected from tuberculosis with regular, low-cost preventive medication. The guidelines present a set of recommendations that will help reduce TB disease in people living with HIV, their families and communities through a combination of screening for TB and provision of IPT.
This advocacy brochure shows how one million lives can be saved by the end of 2015 by preventing and treating tuberculosis among people living with HIV.
WHO and The Union have developed a Collaborative Framework for Care and Control of Tuberculosis and Diabetes, which presents recommendations based on evidence from systematic reviews and a series of expert consultations. It outlines essential steps for coordinated action in three areas: (1) establishment of mechanisms for collaboration between national TB programmes and suitable counterparts responsible for care and control of diabetes; (2) improved detection and management of TB in patients with diabetes; (3) improved detection and management of diabetes in patients with TB.
